Renal therapy value can be defined as the ratio of outcomes achieved by a dialytic therapy to the total cost of providing that therapy. One desirable goal of any dialysis modality would be the achievement of maximum value. Unfortunately, with conventional hemodialysis and peritoneal dialysis modalities, improving outcomes has always been linked to a simultaneous increase in costs, thereby leaving value relatively unchanged. However, a new modality, daily home hemodialysis, finally may allow this linkage to be broken. The outcomes are dramatically improved as a result of a higher quantity and quality of dialysis dose resulting from the greater frequency of treatments. The costs can be reduced by minimizing the consumed items, avoiding the labor and overhead of dialysis clinics, and reducing the costs associated with morbidity. Provision of this therapy is, however, predicated on the availability of instrumentation designed specifically for it because conventional equipment designed for in-center use is not suitable. By starting with a clean sheet of paper and incorporating such features as insitu reuse of the entire extracorporeal circuit, remote telemonitoring, automated system disinfection, and integrated water purification, most of the impediments to performing this modality can be overcome.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1073-4449(96)80054-9DOI Listing

Publication Analysis

Top Keywords

daily hemodialysis
8
renal therapy
8
therapy
5
tearing barriers
4
barriers daily
4
hemodialysis achieving
4
achieving highest
4
highest renal
4
therapy holistic
4
holistic product
4

Similar Publications

Objective: To summarize antiretroviral therapy (ART) use in the setting of end-stage kidney disease (ESKD).

Design: Cross-sectional analysis.

Methods: Descriptive analysis of ART regimens and dose of nucleoside/nucleotide reverse-transcriptase inhibitors (NRTI) in people with HIV and ESKD (dialysis, kidney transplantation, or estimated glomerular filtration rate (eGFR) <15 mL/min/1.

View Article and Find Full Text PDF

Background: The relationship between the psoas muscle gauge (PMG), a combined sarcopenia indicator obtained from psoas muscle index (PMI) and psoas muscle density (PMD), and adverse clinical outcomes in patients on hemodialysis remains unclear. We examined whether psoas muscle gauge could predict all-cause mortality and new cardiovascular events more accurately than psoas muscle index in these patients.

Methods: We retrospectively included 217 hemodialysis patients who underwent abdominal computed tomography.

View Article and Find Full Text PDF

Osmotic demyelination syndrome (ODS) is a rare complication associated with rapid sodium changes, typically encountered in patients with severe hyponatremia. ODS in patients with normonatremia (ODSIN) is less recognized. We describe a patient with MRI-detected ODSIN following neurotrauma and reviewed the relevant literature.

View Article and Find Full Text PDF

Malnutrition is a prevalent complication in hemodialysis patients and is associated with increased mortality and morbidity. This study aimed to identify the risk factors associated with malnutrition among hemodialysis patients including patient's general characteristics, functional status, and dietary intake. This study involved hemodialysis patients in An-Najah National University Hospital at Nablus/Palestine.

View Article and Find Full Text PDF

Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.

Clin Pharmacokinet

January 2025

Laboratoire de Pharmacologie et Toxicologie, Department of Pharmacology, UR 3801, Reims University Hospital, University of Reims Champagne-Ardenne, 45 rue Cognacq Jay, 51092, Reims Cedex, France.

Background And Objective: Apixaban is increasingly being used for stroke prevention in patients with end-stage kidney disease with atrial fibrillation undergoing haemodialysis, but no pharmacostatistical model is available for dosage adjustment. This study aimed to develop a population pharmacokinetic model of apixaban in these patients to characterise its dialytic clearance and determine optimal dosing regimens and discontinuation timing before surgery.

Methods: Patients received 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!